{
  "url": "https://openlegislation.uk/human-medicines-amendments-relating-to-naloxone-and-transfers-of-functions-regulations-2024/regulation-8",
  "json_url": "https://openlegislation.uk/human-medicines-amendments-relating-to-naloxone-and-transfers-of-functions-regulations-2024/regulation-8.json",
  "legislation": "uksi/2024/1125",
  "legislation_title": "The Human Medicines (Amendments Relating to Naloxone and Transfers of Functions) Regulations 2024",
  "legislation_url": "https://openlegislation.uk/human-medicines-amendments-relating-to-naloxone-and-transfers-of-functions-regulations-2024",
  "path": "regulation/8",
  "kind": "regulation",
  "number": "8",
  "heading": "Amendment to regulation 250",
  "text": "In regulation 250 (exceptions to regulation 249), after paragraph (4A) insert—\n“(4B) A person may, in the course of a business consisting (wholly or partly) of manufacturing medicinal products, or of selling products by way of wholesale dealing, sell or supply by way of wholesale dealing a naloxone product that is a prescription only medicine to—\n(a) providers of drug treatment services that have arrangements as mentioned in regulation 237A(2)(a);\n(b) the medical services of His Majesty’s forces;\n(c) the bodies mentioned in regulation 237A(2)(c); and\n(d) local naloxone providers.”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "Amended by S.I. 2020/1125 (S.R. 2020/349)."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2024/1125/regulation/8",
    "retrieved_at": "2026-10-28T21:24:47.176434+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}